What is the price target for GYRE stock?
9 analysts have analysed GYRE and the average price target is 19.04 USD. This implies a price increase of 155.91% is expected in the next year compared to the current price of 7.44.
GYRE THERAPEUTICS INC (GYRE) Forecast, Price Target & Analyst Ratings
NASDAQ:GYRE • US4037831033
Current stock price
7.44 USD
0 (0%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for GYRE THERAPEUTICS INC (GYRE).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 8, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.07
- Revenue Estimate
- 32.239M
Price Target Details & History
Consensus Price Target and Range
Mean target
$19.04
Upside
+ 155.91%
From current price of $7.44 to mean target of $19.04, Based on 9 analyst forecasts
Low
$18.18
Median
$18.36
High
$21.00
Price Target Revisions
1 Month
3.70%
3 Months
3.70%
Price Target Summary
9 Wall Street analysts provided a forecast for the next 12 months for GYRE. The average price target is 19.04 USD. This implies a price increase of 155.91% is expected in the next year compared to the current price of 7.44.
The average price target has been revised upward by 3.7% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
84.44%
GYRE was analyzed by 9 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about GYRE.
In the previous month the buy percentage consensus was at a similar level.
GYRE was analyzed by 9 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-10-10 | Jefferies | Initiate | Buy |
| 2025-08-26 | HC Wainwright & Co. | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 8, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.07
- Revenue Estimate
- 32.239M
- Revenue Q2Q
- 46.16%
- EPS Q2Q
- -349.32%
- Number of Analysts
- 5
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
-8.65%
EPS (1 Month)
0.00%
EPS (3 Months)
-191.66%
Next Earnings Summary
GYRE is expected to report earnings on 5/8/2026. The consensus EPS estimate for the next earnings is -0.07 USD and the consensus revenue estimate is 32.24M USD.
The next earnings revenue estimate has been revised downward by 8.65% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates 2026 - 2033
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 113.45M 14,260.76% | 105.757M -6.78% | 116.588M 10.24% | 139.77M 19.88% | 135.3M -3.20% | 445.94M 229.59% | 271.12M -39.20% | 316.2M 16.63% | 395.76M 25.16% | 397.8M 0.52% | 477.36M 20.00% | |
| EBITDA YoY % growth | 20.287M 169.45% | 17.778M -12.37% | 13.972M -21.41% | -18.87M -235.06% | -23.46M -24.32% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | 19.213M 165.33% | 16.229M -15.53% | 11.491M -29.19% | 306K -97.34% | -4.743M -1,650.00% | 231.54M 4,981.72% | 13.872M -94.01% | 27.54M 98.53% | 133.62M 385.19% | 114.24M -14.50% | 174.42M 52.68% | |
| Operating Margin | 16.94% | 15.35% | 9.86% | 0.22% | -3.51% | 51.92% | 5.12% | 8.71% | 33.76% | 28.72% | 36.54% | |
| EPS YoY % growth | N/A -117.39% | N/A 112.87% | 0.18 -42.86% | -0.33 -281.33% | -0.20 39.06% | 1.98 1,094.87% | 0.68 -65.46% | 0.94 37.31% | 1.55 65.22% | 1.43 -7.89% | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.07 -349.32% | -0.05 -338.02% | -0.08 -206.25% | -0.10 -297.21% |
| Revenue Q2Q % growth | 32.239M 46.16% | 33.616M 25.57% | 35.533M 16.26% | 38.046M 2.29% |
| EBITDA Q2Q % growth | -4.998M -277.99% | -4.998M -249.33% | -4.59M -152.46% | -4.284M -264.71% |
| EBIT Q2Q % growth | -10.2M -548.75% | -11.322M -621.51% | -11.118M -260.55% | -12.036M -10,130.00% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
122.35%
EPS Next 5 Year
39.13%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
56.15%
Revenue Next 5 Year
21.97%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
GYRE THERAPEUTICS INC / GYRE Forecast FAQ
Can you provide the upcoming earnings date for GYRE THERAPEUTICS INC?
GYRE THERAPEUTICS INC (GYRE) will report earnings on 2026-05-08.
What are the consensus estimates for GYRE stock next earnings?
The consensus EPS estimate for the next earnings of GYRE THERAPEUTICS INC (GYRE) is -0.07 USD and the consensus revenue estimate is 32.24M USD.
How many analysts cover GYRE THERAPEUTICS INC (GYRE) stock?
The number of analysts covering GYRE THERAPEUTICS INC (GYRE) is 9.